Entourage Medical Technologies Inc.
Improving transapical access levels the playing field for surgeons
This article was originally published in Start Up
Cardiologist and serial entrepreneur Frank Litvack, best known for founding Conor Medsystems, has picked his first opportunity in interventional structural heart disease. Litvack has co-founded Entourage Medical Technologies Inc. to develop products that support transcatheter interventions for the heart. Entourage is beginning with a transapical access and closure device with the goal of advancing transcatheter aortic valve implantation (TAVI), enabling minimally invasive mitral valve replacement and repairs, and other minimally invasive treatments for patients with structural heart disease.
You may also be interested in...
This month we profile CoolSpine and its catheter-based hypothermia device, Inseal Medical and its large-bore vascular closure device, and MitrAssist Medical, which is developing a valve-in-valve approach to treating mitral regurgitation.
Now that transcatheter heart valves have been implanted in thousands of humans, it’s becoming clear where the problems lie. Vascular and bleeding complications, stroke and paravalvular leaks are the most troubling consequences. Most of the focus has been on improving the valves and the delivery systems, but now innovators are looking at the issue of access – the particular ways by which therapeutic devices enter the heart – and how it can be changed to improve outcomes. In this issue we profile Apica Cardiovascular, Entourage Medical and Inseal Medical.
As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need.